Trial Profile
The effect of mepolizumab on patients with nasal polyp eosinophilia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 01 Dec 2022 Results determining the local effect of mepolizumab on inflammatory biomarkers in sinonasal tissue of eosinophilic chronic rhinosinusitis patients, published in the Clinical and Experimental Allergy
- 24 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Sep 2020 Status changed from recruiting to active, no longer recruiting.